Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

PhIP-Seq characterization of serum antibodies using oligonucleotide-encoded peptidomes

A Publisher Correction to this article was published on 25 October 2018

This article has been updated


The binding specificities of an individual’s antibody repertoire contain a wealth of biological information. They harbor evidence of environmental exposures, allergies, ongoing or emerging autoimmune disease processes, and responses to immunomodulatory therapies, for example. Highly multiplexed methods to comprehensively interrogate antibody-binding specificities have therefore emerged in recent years as important molecular tools. Here, we provide a detailed protocol for performing ‘phage immunoprecipitation sequencing’ (PhIP-Seq), which is a powerful method for analyzing antibody-repertoire binding specificities with high throughput and at low cost. The methodology uses oligonucleotide library synthesis (OLS) to encode proteomic-scale peptide libraries for display on bacteriophage. These libraries are then immunoprecipitated, using an individual’s antibodies, for subsequent analysis by high-throughput DNA sequencing. We have used PhIP-Seq to identify novel self-antigens associated with autoimmune disease, to characterize the self-reactivity of broadly neutralizing HIV antibodies, and in a large international cross-sectional study of exposure to hundreds of human viruses. Compared with alternative array-based techniques, PhIP-Seq is far more scalable in terms of sample throughput and cost per analysis. Cloning and expression of recombinant proteins are not required (versus protein microarrays), and peptide lengths are limited only by DNA synthesis chemistry (up to 90-aa (amino acid) peptides versus the typical 8- to 12-aa length limit of synthetic peptide arrays). Compared with protein microarrays, however, PhIP-Seq libraries lack discontinuous epitopes and post-translational modifications. To increase the accessibility of PhIP-Seq, we provide detailed instructions for the design of phage-displayed peptidome libraries, their immunoprecipitation using serum antibodies, deep sequencing–based measurement of peptide abundances, and statistical determination of peptide enrichments that reflect antibody–peptide interactions. Once a library has been constructed, PhIP-Seq data can be obtained for analysis within a week.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1: Overview of the PhIP-Seq methodology.
Fig. 2: Bioinformatics workflows.
Fig. 3: Primer-depleted, pooled VirScan PCR2 products run at a higher molecular weight than expected (shown on a 2% (wt/vol) agarose gel in lithium borate).
Fig. 4: Organization of bacteriophage genome, primer binding sites, and PCR products.
Fig. 5: Output from the sequencing data analysis pipeline.

Change history

  • 25 October 2018

    The version of this paper originally published contained typesetter-introduced errors in some of the code commands, consisting of conversion of a closing backslash (\) to a forward slash (/). These errors have been corrected in the HTML and PDF versions of the protocol.


  1. 1.

    Larman, H. B. et al. Autoantigen discovery with a synthetic human peptidome. Nat. Biotechnol. 29, 535–541 (2011).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  2. 2.

    Larman, H. B. et al. PhIP-Seq characterization of autoantibodies from patients with multiple sclerosis, type 1 diabetes and rheumatoid arthritis. J. Autoimmun. 43, 1–9 (2013).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  3. 3.

    Larman, H. B. et al. Cytosolic 5′-nucleotidase 1A autoimmunity in sporadic inclusion body myositis. Ann. Neurol. 73, 408–418 (2013).

    Article  CAS  PubMed  Google Scholar 

  4. 4.

    Finton, K. A. et al. Ontogeny of recognition specificity and functionality for the broadly neutralizing anti-HIV antibody 4E10. PLoS Pathog. 10, e1004403 (2014).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. 5.

    Xu, G. J. et al. Viral immunology. Comprehensive serological profiling of human populations using a synthetic human virome. Science 348, aaa0698 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. 6.

    Kosuri, S. & Church, G. M. Large-scale de novo DNA synthesis: technologies and applications. Nat. Methods 11, 499–507 (2014).

    CAS  Article  PubMed  Google Scholar 

  7. 7.

    Atak, A. et al. Protein microarray applications: autoantibody detection and posttranslational modification. Proteomics 16, 2557–2569 (2016).

    CAS  Article  PubMed  Google Scholar 

  8. 8.

    Yu, X. et al. Multiplexed nucleic acid programmable protein arrays. Theranostics 7, 4057–4070 (2017).

    Article  PubMed  PubMed Central  Google Scholar 

  9. 9.

    Henkel, S., Wellhausen, R., Woitalla, D., Marcus, K. & May, C. Epitope mapping using peptide microarray in autoantibody profiling. Methods Mol. Biol. 1368, 209–224 (2016).

    CAS  Article  PubMed  Google Scholar 

  10. 10.

    Finton, K. A. et al. Autoreactivity and exceptional CDR plasticity (but not unusual polyspecificity) hinder elicitation of the anti-HIV antibody 4E10. PLoS Pathog. 9, e1003639 (2013).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  11. 11.

    Xu, G.J. et al. Systematic autoantigen analysis identifies a distinct subtype of scleroderma with coincident cancer. Proc. Natl. Acad. Sci. USA 113, E7526-E7534 (2016).

    CAS  Article  Google Scholar 

  12. 12.

    Zhu, H., Luo, H., Yan, M., Zuo, X. & Li, Q. Z. Autoantigen microarray for high-throughput autoantibody profiling in systemic lupus erythematosus. Genomics Proteomics Bioinformatics 13, 210–218 (2015).

    Article  PubMed  PubMed Central  Google Scholar 

  13. 13.

    Miersch, S. & LaBaer, J. Nucleic acid programmable protein arrays: versatile tools for array-based functional protein studies. Curr. Protoc. Protein Sci. Chapter 27, Unit 27.2 (2011).

  14. 14.

    Zhu, J. et al. Protein interaction discovery using parallel analysis of translated ORFs (PLATO). Nat. Biotechnol. 31, 331–334 (2013).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  15. 15.

    Larman, H. B., Liang, A. C., Elledge, S. J. & Zhu, J. Discovery of protein interactions using parallel analysis of translated ORFs (PLATO). Nat. Protoc. 9, 90–103 (2014).

    CAS  Article  PubMed  Google Scholar 

  16. 16.

    Jhaveri, D. T. et al. Using quantitative seroproteomics to identify antibody biomarkers in pancreatic cancer. Cancer Immunol. Res. 4, 225–233 (2016).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  17. 17.

    MacConaill, L. E. et al. Unique, dual-indexed sequencing adapters with UMIs effectively eliminate index cross-talk and significantly improve sensitivity of massively parallel sequencing. BMC Genomics 19, 30 (2018).

    Article  PubMed  PubMed Central  Google Scholar 

Download references


The development of the PhIP-Seq technology platform has been an ongoing collaboration with S.J. Elledge of the Harvard Medical School Genetics Department and the Howard Hughes Medical Institute. Special thanks to T.M. Shi (Department of Art as Applied to Medicine, Johns Hopkins School of Medicine) for creating the artwork used in Fig. 1. Recent improvements in the PhIP-Seq methodology were supported under a U24 Resource-Related Research Projects Cooperative Agreement awarded by the NIH (U24AI118633 to H.B.L. and S.J. Elledge), a grant from the Jerome L. Greene Foundation (to H.B.L. and A.N.B.), and a grant from the Sjögren’s Syndrome Foundation (to H.B.L. and A.N.B.). A.N.B. received support from NIH grant R01DE012354 (Rosen, PI).

Author information




D.M., D.L.W., and B.M.S. performed experiments related to assay development and optimization. D.M. performed PhIP-Seq screening analysis of the serum samples used in this study. M.S.N. created a draft version of the peptidome design software. A.N.B. provided the Sjogren’s syndrome serum samples and disease-specific expertise. U.L. developed the pepsyn and phip-stat software packages. U.L. and H.B.L. wrote the manuscript.

Corresponding authors

Correspondence to Uri Laserson or H. Benjamin Larman.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Related links

Key references using this protocol

1. Larman, H. B. et al. Nat. Biotech. 29, 535–541 (2011)

2. Larman, H. B. et al. Ann. Neurol. 73, 408–418 (2013)

3. Xu, G. J. et al. Science 384, aaa0698 (2015)

Supplementary information

Supplementary Table 1

Design of 96 ad_min_BCX_P7 PCR2 i7 indexing primers

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Mohan, D., Wansley, D.L., Sie, B.M. et al. PhIP-Seq characterization of serum antibodies using oligonucleotide-encoded peptidomes. Nat Protoc 13, 1958–1978 (2018).

Download citation

Further reading


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing